MA34087B1 - Vaccins recombinants contre le virus de la langue bleue et leurs utilisations - Google Patents

Vaccins recombinants contre le virus de la langue bleue et leurs utilisations

Info

Publication number
MA34087B1
MA34087B1 MA35244A MA35244A MA34087B1 MA 34087 B1 MA34087 B1 MA 34087B1 MA 35244 A MA35244 A MA 35244A MA 35244 A MA35244 A MA 35244A MA 34087 B1 MA34087 B1 MA 34087B1
Authority
MA
Morocco
Prior art keywords
btv
vaccines against
recombinant vaccines
against blue
viruses
Prior art date
Application number
MA35244A
Other languages
Arabic (ar)
English (en)
Inventor
Jean-Christophe Audonnet
Xuan Guo
Kevin Cox
Original Assignee
Merial Ltd
Biolex Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merial Ltd, Biolex Therapeutics filed Critical Merial Ltd
Publication of MA34087B1 publication Critical patent/MA34087B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/15—Reoviridae, e.g. calf diarrhea virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C12N15/8257—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon
    • C12N15/8258—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon for the production of oral vaccines (antigens) or immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/517—Plant cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12111—Orbivirus, e.g. bluetongue virus
    • C12N2720/12134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des vaccins ou des compositions contre le BTV. Il peut s'agir d'un vaccin ou d'une composition contenant des antigènes du BTV. L'invention concerne également des vecteurs recombinants codant pour et exprimant des antigènes, des épitopes ou des immunogènes du BTV qui peuvent être utilisés pour protéger des animaux tels que des ovins, des bovins ou des caprins contre le BTV.
MA35244A 2010-03-12 2011-03-11 Vaccins recombinants contre le virus de la langue bleue et leurs utilisations MA34087B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31316410P 2010-03-12 2010-03-12
US36636310P 2010-07-21 2010-07-21
PCT/US2011/028131 WO2011112955A1 (fr) 2010-03-12 2011-03-11 Vaccins recombinants contre le virus de la langue bleue et leurs utilisations

Publications (1)

Publication Number Publication Date
MA34087B1 true MA34087B1 (fr) 2013-03-05

Family

ID=43923659

Family Applications (1)

Application Number Title Priority Date Filing Date
MA35244A MA34087B1 (fr) 2010-03-12 2011-03-11 Vaccins recombinants contre le virus de la langue bleue et leurs utilisations

Country Status (15)

Country Link
US (3) US9345759B2 (fr)
EP (4) EP2545067B1 (fr)
JP (1) JP2013522300A (fr)
CN (2) CN103687614B (fr)
AR (1) AR080515A1 (fr)
AU (1) AU2011224188B2 (fr)
BR (2) BR112012023852B1 (fr)
CA (2) CA2792117C (fr)
ES (2) ES2795148T3 (fr)
IL (3) IL221781B (fr)
MA (1) MA34087B1 (fr)
NZ (2) NZ702145A (fr)
RU (1) RU2575599C2 (fr)
WO (2) WO2011112945A2 (fr)
ZA (1) ZA201206619B (fr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008230795B2 (en) 2007-03-27 2014-05-29 Bioassets, Llc Constructs and libraries comprising antibody surrogate light chain sequences
US20120128671A1 (en) 2009-05-13 2012-05-24 Lawrence Horowitz Neutralizing molecules to influenza viruses
BR112012010357B1 (pt) 2009-11-02 2022-05-24 Inovio Pharmaceuticals, Inc. Proteínas de consenso de vírus de doença de febre aftosa (fmdv), sequências de codificação para as mesmas e vacinas feitas a partir das mesmas
CA2842860A1 (fr) 2011-07-28 2013-01-31 Sea Lane Biotechnologies, Llc Proteines se liant a sur dirigees contre erbb3
US9975956B2 (en) 2011-12-22 2018-05-22 I2 Pharmaceuticals, Inc. Surrogate binding proteins which bind DR4 and/or DR5
MX386517B (es) 2012-09-05 2025-03-19 Medicago Inc Produccion de particulas similares a picornavirus en plantas.
US20140090108A1 (en) * 2012-09-18 2014-03-27 Freydoun Garabagi Vectors and Methods For Enhancing Recombinant Protein Expression in Plants
WO2014145951A2 (fr) * 2013-03-15 2014-09-18 The Trustees Of The University Of Pennsylvania Protéines consensus du virus de la fièvre aphteuse (fmdv), séquences codant pour celles-ci et vaccins obtenus de celles-ci
BR112015024391A2 (pt) * 2013-03-26 2017-10-24 The Pirbright Inst mutante de proteína, capsídeo, método para melhorar a estabilidade de um capsídeo, molécula de ácido nucleico isolada, célula hospedeira, micro-organismo recombinante carreador vivo, vacina, uso de um mutante da proteína vp2, e, métodos para preparar uma vacina e um mutante da proteína
US10872313B2 (en) 2015-06-02 2020-12-22 ROCA Medical Ltd. Method for repurposing NDC codes in a pharmaceutical database for venom derived allergens involved in venom immunotherapy
US10010605B2 (en) * 2014-09-23 2018-07-03 Merial, Inc. FMDV recombinant vaccines and uses thereof
CN111925423B (zh) * 2014-11-07 2022-08-19 普莱柯生物工程股份有限公司 一种抗o型口蹄疫的疫苗组合物及其制备方法和应用
US10369215B2 (en) 2015-06-02 2019-08-06 ROCA Medical Ltd. Predilution sets for distributing antigens
US10548974B2 (en) 2015-06-02 2020-02-04 ROCA Medical Ltd. Therapeutic treatment kit for allergies based on DNA profiles
US11103570B2 (en) * 2015-06-15 2021-08-31 Bavarian Nordic A/S Recombinant modified vaccinia virus Ankara (MVA) foot and mouth disease virus (FMDV) vaccine
JP6797206B2 (ja) * 2015-11-23 2020-12-09 ベーリンガー インゲルハイム アニマル ヘルス ユーエスエイ インコーポレイテッド Ｆｍｄｖ及びｅ２融合タンパク質並びにその使用
WO2017097875A1 (fr) * 2015-12-08 2017-06-15 Danmarks Tekniske Universitet Kit d'éléments pour utilisation dans le cadre d'une stratégie de primo-vaccination/rappel visant à protéger des animaux biongulés contre une infection par le virus de la fièvre aphteuse
TWI730037B (zh) * 2016-01-26 2021-06-11 日商富士軟片和光純藥股份有限公司 光硬化方法，及用於該光硬化方法之化合物和組成物
TWI760322B (zh) * 2016-01-29 2022-04-11 美商百靈佳殷格翰動物保健美國有限公司 重組腺病毒載體裝載之fmdv疫苗及其用途
US11053509B2 (en) 2016-04-19 2021-07-06 Csir Plant-produced chimaeric Orbivirus VLPs
US10435695B2 (en) 2016-09-08 2019-10-08 The Government of the United States of America, as represented by the Secretary of Homeland Security Fusion protein comprising Gaussia luciferase, translation interrupter sequence, and interferon amino acid sequences
US10385319B2 (en) * 2016-09-08 2019-08-20 The Governement of the United States of America, as represented by the Secretary of Homeland Security Modified foot-and-mouth disease virus 3C proteases, compositions and methods thereof
WO2019023920A1 (fr) * 2017-08-01 2019-02-07 金普诺安生物科技（苏州）有限公司 Vaccin à particules de type virus de la fièvre aphteuse et son procédé de préparation
KR102165358B1 (ko) * 2017-12-29 2020-10-14 (주)플럼라인생명과학 구제역 바이러스 a형 백신 조성물
CN108273054B (zh) * 2018-01-25 2020-11-17 中国农业科学院兰州兽医研究所 猪口蹄疫病毒O型、A型Fc多肽双价疫苗及其制备方法和应用
CN111233984B (zh) * 2018-11-29 2022-08-12 普莱柯生物工程股份有限公司 一种o型口蹄疫病毒样颗粒抗原、及其疫苗组合物、制备方法和应用
CA3185141A1 (fr) 2020-05-27 2021-12-02 The United States Of America, As Represented By The Secretary Of Agriculture Souches attenuees vivantes de fievre aphteuse modifiees par desoptimisation et leurs utilisations
CN117801099B (zh) * 2023-12-11 2024-08-30 中国农业科学院兰州兽医研究所 一株抗蓝舌病毒vp7蛋白的重组单克隆抗体

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2909462A (en) 1955-12-08 1959-10-20 Bristol Myers Co Acrylic acid polymer laxative compositions
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US5110587A (en) 1981-12-24 1992-05-05 Health Research, Incorporated Immunogenic composition comprising synthetically modified vaccinia virus
US5505941A (en) 1981-12-24 1996-04-09 Health Research, Inc. Recombinant avipox virus and method to induce an immune response
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US5174993A (en) 1981-12-24 1992-12-29 Health Research Inc. Recombinant avipox virus and immunological use thereof
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
CA1247080A (fr) 1983-03-08 1988-12-20 Commonwealth Serum Laboratories Commission Sequences d'acides amines ayant une activite antigenique
US5380831A (en) 1986-04-04 1995-01-10 Mycogen Plant Science, Inc. Synthetic insecticidal crystal protein gene
US4761373A (en) 1984-03-06 1988-08-02 Molecular Genetics, Inc. Herbicide resistance in plants
EP0173552B1 (fr) 1984-08-24 1991-10-09 The Upjohn Company Composés recombinants d'ADN et l'expression de polypeptides comme le tPA
US4945050A (en) 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4963481A (en) 1985-12-18 1990-10-16 Genetics Institute Inc Promoter system
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
WO1987004181A1 (fr) 1986-01-08 1987-07-16 Rhone-Poulenc Agrochimie Gene decomposant l'haloarylnitrile, son utilisation et cellules le contenant
GB2197321B (en) 1986-09-12 1990-10-03 Genentech Inc Method and vectors for obtaining continuous production of heterologous protein in a eukaryotic host cell line
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
DE3743138A1 (de) 1987-12-18 1989-09-14 Mayr Christian Gmbh & Co Kg Schleifringlose, elektromagnetische ueberlastkupplung
CA1341245C (fr) 1988-01-12 2001-06-05 F. Hoffmann-La Roche Ag Virus recombinant de la vaccine derive du virus modifie ankara
US5990387A (en) 1988-06-10 1999-11-23 Pioneer Hi-Bred International, Inc. Stable transformation of plant cells
NZ230375A (en) 1988-09-09 1991-07-26 Lubrizol Genetics Inc Synthetic gene encoding b. thuringiensis insecticidal protein
EP1103616A3 (fr) 1989-02-24 2001-06-27 Monsanto Company Gènes synthétiques de plantes et méthode pour leur préparation
US5879918A (en) 1989-05-12 1999-03-09 Pioneer Hi-Bred International, Inc. Pretreatment of microprojectiles prior to using in a particle gun
GB8915572D0 (en) * 1989-07-07 1989-08-23 Natural Environment Res Use of bluetongue virus proteins as vaccine components
US5690938A (en) 1989-07-07 1997-11-25 Oravax, Inc. Oral immunization with multiple particulate antigen delivery system
WO1991016432A1 (fr) 1990-04-18 1991-10-31 Plant Genetic Systems N.V. Genes modifies du bacillus thuringiensis codant une proteine cristalline insecticide et leur expression dans des cellules de plantes
US5932782A (en) 1990-11-14 1999-08-03 Pioneer Hi-Bred International, Inc. Plant transformation method using agrobacterium species adhered to microprojectiles
EP0575491B1 (fr) 1991-03-07 2003-08-13 Virogenetics Corporation Souche de vaccin mise au point par genie genetique
TW261517B (fr) 1991-11-29 1995-11-01 Mitsubishi Shozi Kk
AU670316B2 (en) 1992-07-27 1996-07-11 Pioneer Hi-Bred International, Inc. An improved method of (agrobacterium)-mediated transformation of cultured soybean cells
WO1995014098A1 (fr) 1993-11-19 1995-05-26 Biotechnology Research And Development Corporation Regions regulatrices chimeres et cassettes de genes destines a l'expression de genes dans des plantes
JPH11504631A (ja) 1995-04-25 1999-04-27 バイカル インコーポレイテッド Ｄｎａ／脂質複合体の単一バイアル製剤
US5846946A (en) 1996-06-14 1998-12-08 Pasteur Merieux Serums Et Vaccins Compositions and methods for administering Borrelia DNA
FR2751229B1 (fr) 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique notamment contre la pathologie respiratoire des bovins
FR2751226B1 (fr) 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique contre les pathologies du cheval
FR2751225B1 (fr) 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique aviaire
FR2751224B1 (fr) 1996-07-19 1998-11-20 Rhone Merieux Formule de vaccin polynucleotidique contre les pathologies respiratoires et de reproduction des porcs
FR2751227B1 (fr) 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique contre les pathologies canines, notamment les pathologies respiratoires et digestives
FR2751228B1 (fr) 1996-07-19 1998-11-20 Rhone Merieux Vaccin polynucleotidique bovin pour voie intradermique
WO1998016247A1 (fr) 1996-10-11 1998-04-23 The Regents Of The University Of California Conjugues polynucleotide immunostimulateur/molecule immunomodulatrice
US6045774A (en) 1997-01-10 2000-04-04 Epicyte Pharmaceutical Inc. J chain polypeptide targeting molecule linked to an imaging agent
US5981840A (en) 1997-01-24 1999-11-09 Pioneer Hi-Bred International, Inc. Methods for agrobacterium-mediated transformation
CA2294793A1 (fr) 1997-06-30 1999-01-14 Rhone-Poulenc Rorer S.A. Amelioration du transfert d'acide nucleique dans le muscle strie et combinaison permettant la mise en oeuvre du procede
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
US7161064B2 (en) 1997-08-12 2007-01-09 North Carolina State University Method for producing stably transformed duckweed using microprojectile bombardment
FR2778858B1 (fr) 1998-05-20 2000-06-16 Oreal Emulsion e/h/e stable et son utilisation comme composition cosmetique et/ou dermatologique
US8003772B2 (en) 1999-01-14 2011-08-23 Martek Biosciences Corporation Chimeric PUFA polyketide synthase systems and uses thereof
FR2801607B1 (fr) 1999-11-26 2001-12-28 Merial Sas Pneumovirus du canard et vaccins correspondants
US6852705B2 (en) 2000-01-21 2005-02-08 Merial DNA vaccines for farm animals, in particular bovines and porcines
FR2810888B1 (fr) 2000-06-29 2004-07-30 Merial Sas Vaccin contre la fievre aphteuse
US7632983B2 (en) * 2000-07-31 2009-12-15 Biolex Therapeutics, Inc. Expression of monoclonal antibodies in duckweed
NZ523912A (en) 2000-07-31 2005-03-24 Biolex Inc Expression of biologically active polypeptides in duckweed
US8022270B2 (en) * 2000-07-31 2011-09-20 Biolex Therapeutics, Inc. Expression of biologically active polypeptides in duckweed
US7018164B2 (en) 2000-09-06 2006-03-28 The Charles Machine Works, Inc. Auxiliary pipe loading device
TWI377253B (en) 2001-04-16 2012-11-21 Martek Biosciences Corp Product and process for transformation of thraustochytriales microorganisms
AU2002257341B2 (en) 2001-05-30 2008-01-31 Synthon Biopharmaceuticals B.V. Use of duckweed in high throughput screening
RU2207877C1 (ru) * 2001-11-09 2003-07-10 Всероссийский научно-исследовательский институт экспериментальной ветеринарии им. Я.Р. Коваленко Вакцина для профилактики и лечения трихофитии крупного, мелкого рогатого скота и оленей
US6680200B2 (en) 2002-02-22 2004-01-20 Biolex, Inc. Led array for illuminating cell well plates and automated rack system for handling the same
CA2478294C (fr) * 2002-03-19 2013-09-03 Plant Research International B.V. Expression de gntiii (udp-n-acetylglucosamine:beta-d mannoside beta (1,4)-n-acetylglucosaminyltransferase iii) dans des plantes
US7176024B2 (en) 2003-05-30 2007-02-13 Biolex, Inc. Bioreactor for growing biological materials supported on a liquid surface
PL1651265T3 (pl) 2003-07-24 2008-10-31 Merial Ltd Formulacje szczepionek zawierających emulsję olej w wodzie
US7527960B2 (en) * 2004-06-25 2009-05-05 Merial Limited Avipox recombinants expressing foot and mouth disease virus genes
CN100582122C (zh) * 2006-05-12 2010-01-20 北京宝麦德生物医药科技有限责任公司 O型口蹄疫病毒多表位粘膜免疫疫苗及其应用
US7862821B2 (en) 2006-06-01 2011-01-04 Merial Limited Recombinant vaccine against bluetongue virus
CN101082051A (zh) * 2006-06-02 2007-12-05 广东出入境检验检疫局检验检疫技术中心 重组口蹄疫病毒多肽片段及其应用
CN101121938B (zh) * 2007-03-23 2010-10-06 中国农业科学院兰州兽医研究所 一种口蹄疫抗原的制备方法
WO2009076778A1 (fr) 2007-11-27 2009-06-25 Medicago Inc. Particules pseudovirales (vlp) de la grippe recombinées produites dans des plantes transgéniques exprimant l'hémagglutinine
KR101718497B1 (ko) * 2007-11-26 2017-03-22 런던 스쿨 오브 하이진 앤 트로피컬 메디신 레오바이러스과 바이러스의 백신용 바이러스 균주를 제조하는 방법
WO2009128043A1 (fr) * 2008-04-16 2009-10-22 Onderstepoort Biological Products Ltd Vaccin contre le virus vivant atténué inactivé de la fièvre catarrhale ovine
TW201010719A (en) * 2008-08-19 2010-03-16 Wyeth Corp Immunological composition
MX2011005604A (es) * 2008-11-28 2011-09-01 Merial Ltd Vacuna recombinante para influenza aviar y sus usos.
CN102648207A (zh) 2009-03-16 2012-08-22 马太克生物科学公司 在网粘菌门微生物中产生蛋白质

Also Published As

Publication number Publication date
US20110236420A1 (en) 2011-09-29
ZA201206619B (en) 2013-05-29
JP2013522300A (ja) 2013-06-13
CN103687614B (zh) 2018-06-08
AR080515A1 (es) 2012-04-11
US9345759B2 (en) 2016-05-24
BR112012023046A2 (pt) 2017-07-18
US20110236416A1 (en) 2011-09-29
WO2011112945A3 (fr) 2011-11-10
CA2792118C (fr) 2022-07-12
EP2545067A1 (fr) 2013-01-16
CA2792117C (fr) 2016-09-20
ES2795148T3 (es) 2020-11-20
IL221781B (en) 2018-12-31
EP2545067B1 (fr) 2016-11-30
EP2944322A2 (fr) 2015-11-18
IL263249B (en) 2020-05-31
RU2575599C2 (ru) 2016-02-20
WO2011112945A2 (fr) 2011-09-15
NZ602278A (en) 2014-12-24
AU2011224188B2 (en) 2015-01-22
CA2792118A1 (fr) 2011-09-15
US20170022255A1 (en) 2017-01-26
BR112012023852A2 (pt) 2017-03-21
BR112012023046B1 (pt) 2020-04-07
ES2617743T3 (es) 2017-06-19
WO2011112955A1 (fr) 2011-09-15
BR112012023852B1 (pt) 2020-11-10
RU2012143624A (ru) 2014-04-20
IL263253A (en) 2018-12-31
EP2544716A2 (fr) 2013-01-16
EP2944322B1 (fr) 2018-01-17
EP2944322A3 (fr) 2015-12-16
EP2544716B1 (fr) 2020-01-01
EP3093025B1 (fr) 2018-08-01
CN103687614A (zh) 2014-03-26
EP3093025A1 (fr) 2016-11-16
NZ702145A (en) 2016-03-31
CN103492410A (zh) 2014-01-01
AU2011224188A1 (en) 2012-09-27
IL263249A (en) 2018-12-31
CA2792117A1 (fr) 2011-09-15
IL263253B (en) 2020-07-30

Similar Documents

Publication Publication Date Title
MA40151B2 (fr) Vaccins de recombinaison fmdv et leurs utilisations
JOP20170022B1 (ar) لقاحات التهاب العين الفيروسي المهجنة المنقولة بواسطة اف ام دي في و استخداماتها
NZ602278A (en) Bluetongue virus recombinant vaccines and uses thereof
WO2012027365A3 (fr) Formes pharmaceutiques multi-épitopes ciblées servant à l'induction d'une réponse immunitaire dirigée contre des antigènes
MY169331A (en) Vaccine against rsv
EA201001491A1 (ru) Репликационно-дефектные вакцины и вакцинные векторы против флавивирусов
MX344103B (es) Vacunas de virus herpes vectorizado con virus de enfermedad de newcastle.
EA201400912A1 (ru) Рекомбинантные поксвирусные векторы, экспрессирующие белки вируса бешенства и ox40, и вакцины, созданные на их основе
MX352478B (es) Proteina vp6 de la capside de norovirus y rotavirus para el uso como vacuna combinada.
PH12017501370A1 (en) Bivalent swine influenza virus vaccine
AR080313A1 (es) Composiciones de virus de moquillo canino (cdv) recombinante y sus usos
HK1213478A1 (zh) 鱼用亚单位浸泡疫苗
MA37749B1 (fr) Vaccins contre les virus réassortis de la fièvre catarrhale et de la peste équine
MX2017005687A (es) Metodos para usar formulaciones para vacuna con microagujas para elicitar en animales inmunidad protectora contra virus de la rabia.
WO2007024947A3 (fr) Vaccins contre la grippe canine
CO6700818A2 (es) Vectores de parapoxvirus
MX2010008170A (es) Vacunas para influenza canina.
PH12018500372B1 (en) Fcv recombinant vaccines and uses thereof
IL259451B (en) A live virus containing an attenuated dengue virus and a dengue vaccine containing identical antigens
PH12014502086B1 (en) Vaccine against rsv